Multiply Labs, a San Francisco-based robotics startup developing autonomous systems for biologics manufacturing, announced a $75 million Series B funding round on Tuesday. Led by Dr. Patrick Soon-Shiong with NantWorks, the financing brings the company’s total capital raised to more than $100 million since its founding in 2016. Returning investors, including Lux Capital and Founders Fund, were joined by new strategic investors AstraZeneca, Lingotto, Teradyne, and Strange Ventures to support the company’s next phase of commercial-scale deployment.
The funding comes as advances in AI-driven drug discovery accelerate the development of new therapies, placing increasing pressure on pharmaceutical manufacturers to scale production. Multiply Labs aims to address this bottleneck through autonomous robotic systems that reduce manual intervention, improve manufacturing efficiency, and lower production costs. The company’s technology promises to reduce manufacturing costs per dose by up to 74% while increasing throughput per square foot by as much as 100 times compared with traditional manual processes.
Funding Overview
The $75 million Series B was led by Dr. Patrick Soon-Shiong with NantWorks, his biotechnology and technology investment organization. New investors included AstraZeneca, Lingotto, Teradyne, and Strange Ventures, alongside returning investors Casdin Capital, Lux Capital, Fifty Years, Ora Global, and Founders Fund.
The financing brings Multiply Labs’ cumulative funding to more than $100 million and will support expanded manufacturing capacity, accelerated product development, and growth across its engineering, regulatory, and commercial teams. The investment positions the company to transition from early-stage deployments toward commercial-scale production.
Physical AI Platform
Multiply Labs develops autonomous robotic clusters designed to integrate with pharmaceutical manufacturers’ existing equipment and production workflows. Rather than requiring companies to replace established infrastructure or redesign validated processes, its instrument-agnostic platform automates repetitive manufacturing tasks within enclosed, GMP-compliant environments.
Leveraging imitation learning and NVIDIA-powered AI simulation, Multiply Labs is developing systems that can replicate complex laboratory techniques traditionally performed by skilled technicians. By automating manual handoffs and repetitive processes, the technology aims to reduce contamination risks, improve consistency, and increase manufacturing throughput.
The platform initially focused on cell and gene therapies and is expanding into advanced biologics, including antibodies, viral vectors, and mRNA-based treatments. According to Multiply Labs, its technology can reduce manufacturing costs per dose by 74% and increase throughput per square foot by up to 100 times compared with manual manufacturing.
Customer Traction
Multiply Labs has established commercial relationships with major pharmaceutical companies, including AstraZeneca and Legend Biotech, which have purchased and deployed its robotic systems at their facilities. Beyond equipment sales, the company generates recurring revenue through proprietary consumable cartridges and ongoing service and support contracts.
Although its installed base remains relatively small, CEO Fred Parietti has described the number of deployed systems as being in the high single digits, reflecting the company’s early stage of commercial expansion.
Multiply Labs has also strengthened its technology ecosystem through collaborations with industry leaders, including Thermo Fisher Scientific, whose DynaCellect magnetic separation technology has been integrated into its robotic platform.
In May 2026, the company further expanded its international presence by establishing an Italian subsidiary led by Enrico Racca, formerly a supply-chain and manufacturing executive at Scuderia Ferrari’s Formula 1 operation. The expansion brings additional manufacturing and operational expertise as Multiply Labs prepares to scale production.
Scaling Strategy
The new funding will accelerate Multiply Labs’ transition from limited deployments to commercial-scale manufacturing. Key priorities include increasing robotic cluster production capacity, expanding its manufacturing operations in Italy, and strengthening the engineering, regulatory, and commercial teams required to support larger pharmaceutical customers.
The company also aims to substantially reduce the cost of producing its robotic systems. Currently costing several million dollars per unit, Multiply Labs envisions eventually bringing manufacturing costs down to tens of thousands of dollars, making its technology accessible to a broader range of pharmaceutical manufacturers.
Unlike outsourced manufacturing providers, Multiply Labs enables pharmaceutical companies to own and operate its robotic systems within their existing facilities. This approach allows customers to maintain control over manufacturing processes, proprietary data, and supply-chain infrastructure while benefiting from advanced automation.
Why Zillionize Invested
Advances in drug discovery are creating unprecedented opportunities to develop new therapies, but manufacturing remains a critical bottleneck in bringing those treatments to patients. Multiply Labs is addressing this challenge through an innovative combination of robotics, artificial intelligence, and scalable manufacturing technology.
The company’s autonomous, instrument-agnostic robotic clusters offer a compelling solution to the cost, complexity, and scalability challenges facing biologics manufacturing. Its early commercial traction with leading pharmaceutical companies, including AstraZeneca and Legend Biotech, provides meaningful validation of both the technology and its market potential.
Equally important, Multiply Labs’ leadership team has demonstrated the technical expertise and execution capabilities needed to transform MIT-born innovations into commercially deployed systems. We believe the company’s approach has the potential to fundamentally reshape how advanced therapies are manufactured, making life-changing treatments more accessible to patients worldwide.
Multiply Labs exemplifies Zillionize’s commitment to backing visionary founders who combine breakthrough engineering with scalable business models to transform industries and create lasting impact.